Edgewise Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Boulder CO United States (2017)

Organization Overview

First Clinical Trial
2020
NCT04585464
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Edgewise Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

edg-5506 (8 trials)

Drugs in Phase 1 Trials (1)

edg-7500 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Muscular Dystrophies (Phase 1)

Muscular Dystrophy, Duchenne (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 2